Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 1
2006 2
2007 5
2008 2
2009 2
2010 4
2011 5
2012 7
2013 7
2014 6
2015 5
2016 3
2017 1
2018 5
2019 3
2020 4
2021 9
2022 5
2023 7
2024 7
2025 9
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Tutt ANJ, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. N Engl J Med. 2021. PMID: 34081848 Free PMC article. Clinical Trial.
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators. Geyer CE Jr, et al. Ann Oncol. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10. Ann Oncol. 2022. PMID: 36228963 Free PMC article. Clinical Trial.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. von Minckwitz G, et al. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. N Engl J Med. 2017. PMID: 28581356 Free PMC article. Clinical Trial.
MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations.
Lubinski J, Kotsopoulos J, Moller P, Pal T, Eisen A, Peck L, Karlan BY, Aeilts A, Eng C, Bordeleau L, Foulkes WD, Tung N, Couch FJ, Fruscio R, Ramon Y Cajal T, Singer CF, Neuhausen SL, Zakalik D, Cybulski C, Gronwald J, Huzarski T, Stempa K, Dungan J, Cullinane C, Olopade OI, Metcalfe K, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Lubinski J, et al. Among authors: bordeleau l. JAMA Oncol. 2024 Apr 1;10(4):493-499. doi: 10.1001/jamaoncol.2023.6944. JAMA Oncol. 2024. PMID: 38421676 Free PMC article.
Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis.
Metcalfe K, Huzarski T, Gronwald J, Kotsopoulos J, Kim R, Moller P, Pal T, Aeilts A, Eisen A, Karlan B, Bordeleau L, Tung N, Olopade O, Zakalik D, Singer CF, Foulkes W, Couch F, Neuhausen SL, Eng C, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group. Metcalfe K, et al. Among authors: bordeleau l. Br J Cancer. 2024 Feb;130(2):269-274. doi: 10.1038/s41416-023-02503-8. Epub 2023 Nov 29. Br J Cancer. 2024. PMID: 38030749 Free PMC article.
Incidence of endometrial cancer in BRCA mutation carriers.
Kotsopoulos J, Lubinski J, Huzarski T, Bychkovsky BL, Moller P, Kim RH, Tung N, Eisen A, Foulkes W, Singer CF, Aeilts A, Neuhausen SL, Bordeleau L, Karlan B, Fruscio R, Eng C, Olopade O, Zakalik D, Couch F, Y Cajal TR, Sun P, Gronwald J, Narod SA. Kotsopoulos J, et al. Among authors: bordeleau l. Gynecol Oncol. 2024 Oct;189:148-155. doi: 10.1016/j.ygyno.2024.07.687. Epub 2024 Aug 21. Gynecol Oncol. 2024. PMID: 39173195
Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations.
Kotsopoulos J, Gronwald J, Huzarski T, Møller P, Pal T, McCuaig JM, Singer CF, Karlan BY, Aeilts A, Eng C, Eisen A, Bordeleau L, Foulkes WD, Tung N, Couch FJ, Fruscio R, Neuhausen SL, Zakalik D, Cybulski C, Metcalfe K, Olopade OI, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group. Kotsopoulos J, et al. Among authors: bordeleau l. JAMA Oncol. 2024 Apr 1;10(4):484-492. doi: 10.1001/jamaoncol.2023.6937. JAMA Oncol. 2024. PMID: 38421677 Free PMC article.
The risk of skin cancer in women who carry BRCA1 or BRCA2 mutations.
Narod SA, Metcalfe K, Finch A, Chan AW, Armel SR, Aeilts A, Eisen A, Karlan B, Bordeleau L, Tung N, Foulkes WD, Neuhausen SL, Eng C, Olopade O, Zakalik D, Couch F, Cullinane C, Pal T, Sun P, Kotsopoulos J; Hereditary Breast Cancer Clinical Research Group. Narod SA, et al. Among authors: bordeleau l. Hered Cancer Clin Pract. 2024 May 13;22(1):7. doi: 10.1186/s13053-024-00277-5. Hered Cancer Clin Pract. 2024. PMID: 38741145 Free PMC article.
Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant.
Apostol AI, Kotsopoulos J, Gronwald J, Kim RH, Karlan BY, Aeilts A, Cajal TRY, Pal T, Eisen A, Bordeleau L, Foulkes WD, Couch F, Zakalik D, Fruscio R, Sun P, Lubinski J, Tung N, Singer CF, Moller P, Dominguez-Valentin M, Narod SA, Metcalfe K; Hereditary Breast Cancer Clinical Study Group. Apostol AI, et al. Among authors: bordeleau l. Gynecol Oncol. 2025 Oct;201:44-52. doi: 10.1016/j.ygyno.2025.07.030. Epub 2025 Aug 9. Gynecol Oncol. 2025. PMID: 40784323
Parity, breastfeeding, and the risk of early-onset breast cancer in women with a BRCA1 pathogenic variant.
Kotsopoulos J, Maxwell CA, Lubinski J, Huzarski T, Kim RH, Tung N, Eisen A, Foulkes W, Aeilts A, Neuhausen SL, Bordeleau L, Khokha R, Pal T, Karlan B, Fruscio R, Couch F, Sun P, Gronwald J, Narod SA; Hereditary Breast Cancer Clinical Study Group. Kotsopoulos J, et al. Among authors: bordeleau l. Br J Cancer. 2025 Jul;133(1):104-110. doi: 10.1038/s41416-025-03029-x. Epub 2025 May 2. Br J Cancer. 2025. PMID: 40316726
89 results